Status:
COMPLETED
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
Lead Sponsor:
Leiden University Medical Center
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.
Detailed Description
Background of the study: Therapy with radioiodine (RaI) is the only curative therapy in non-medullary thyroid carcinoma. RaI uptake is frequently lost in this disease. Therapy with tyrosine kinase in...
Eligibility Criteria
Inclusion
- Patients with non-medullary thyroid carcinoma
- The patients must have undergone total thyroidectomy
- Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor
- No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy
Exclusion
- Pregnancy
- Other active malignancies
- Active kidney, liver or pancreatic disease or dysfunction
- Unstable angina pectoris or recent (\<3 months) myocardial infarction.
- Coagulopathy
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00887107
Start Date
October 1 2007
Last Update
April 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands, 2300 RC